GoutNCT06969469
To Evaluate the Influence of (LUA Probiotics) on Uric Acid
An observational study of Gout, run by Grape King Bio Ltd. at 1 site in Taiwan.
Trial summary
This study aims to investigate the efficacy of the lactic acid bacteria "LUA probiotics" in reducing serum uric acid levels. The use of health supplements prior to the onset of gout symptoms is proposed as a preventive strategy to mitigate the development of gout and to reduce the subsequent reliance on long-term… Read more about this study
- Who is it for?
- Ages 20 to 90 years
- Conditions the study is for
- Gout
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteTaiwan
- Study dates
- 18 Jul 2022to 8 Aug 2024
- How long will I take part?
- 3 Weeks
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 1. Collect 20 people, both male and female, aged 20 or above. 2. Be conscious, willing to participate in the clinical observational research project, and complete the signed written consent form. 3. Patients with hyperuricemia (uric acid level above 7.5 mg/dL) who have not taken uric acid-lowering drugs, and patients with gout who have not taken uric acid-lowering drugs, regardless of gender.
Who may be able to join
- Collect 20 people, both male and female, aged 20 or above.
- Be conscious, willing to participate in the clinical observational research project, and complete the signed written consent form.
- Patients with hyperuricemia (uric acid level above 7.5 mg/dL) who have not taken uric acid-lowering drugs, and patients with gout who have not taken uric acid-lowering drugs, regardless of gender.
Who cannot join
- Patients diagnosed by a physician as suffering from a major injury or illness listed by the National Health Insurance Administration.
- Pregnant women or women who plan to become pregnant within six months.
- Patients with abnormal liver function (AST, ALT greater than 2 times the upper limit of normal).
- Patients with abnormal renal function (serum creatinine > 1.5 mg/dL).
- Patients with gastrointestinal dysfunction (surgery, frequent diarrhea).
- Those who must continue to take antibiotics, histamine-2 antagonists, proton pump inhibitors, antioxidants, probiotics, laxatives and other drugs.
Show all 11Show fewer
- Patients with serious complications such as stroke, myocardial infarction, or major trauma or surgery in the past six months.
- People who are allergic to Lactobacillus.
- Subjects who are unable to exercise their right to consent on their own.
- Those who have irregular eating habits and are unable to cooperate with the plan implementation.
- Those who have poor compliance with doctor's orders.
Trial locations and contacts
1 site in 1 country.
About this study
This study aims to investigate the efficacy of the lactic acid bacteria "LUA probiotics" in reducing serum uric acid levels. The use of health supplements prior to the onset of gout symptoms is proposed as a preventive strategy to mitigate the development of gout and to reduce the subsequent reliance on long-term pharmacological treatments. Hyperuricemia is the presence of abnormally high levels of uric acid in the blood serum. Long-term hyperuricemia is a major factor in causing gout. In addition, hyperuricemia is associated with many diseases. Therefore, the prevention and treatment of hyperuricemia has gradually attracted attention. In recent years, studies have pointed out that whether from cell experiments or animal experiments, lactic acid bacteria (LAB) have the effect of lowering uric acid. However, there is a lack of rigorous clinical observational studies to further explore whether lactic acid bacteria really have the effect of lowering uric acid. This product "LUA Probiotics" is a probiotic developed and produced by the Longtan Branch of Grape King Biotechnology Co., Ltd. Its main ingredients include Lactobacillus reuteri (Lactobacillus reuteri), β-carotene, silicon dioxide and magnesium stearate. This product is not yet commercially available.
Read the detailed description
This study aims to investigate the efficacy of the lactic acid bacteria "LUA probiotics" in reducing serum uric acid levels. The use of health supplements prior to the onset of gout symptoms is proposed as a preventive strategy to mitigate the development of gout and to reduce the subsequent reliance on long-term pharmacological treatments. In recent years, lactic acid bacteria have gradually been recognized to have many benefits for human health, especially in regulating intestinal flora, enhancing immune function, and improving metabolism. Uric acid is a product of purine metabolism in the human body. Excessive uric acid concentration can cause hyperuricemia, which in turn increases the risk of gout attacks. The formation of hyperuricemia is related to multiple factors, including poor eating habits, genetic factors, and metabolic disorders.
As research on intestinal microbiota deepens, scientists have discovered that changes in intestinal flora may have a certain impact on metabolic diseases, including hyperuricemia. As an important type of probiotics, lactic acid bacteria have the ability to improve the structure of intestinal flora, regulate immune response and have anti-inflammatory effects. Recent studies have shown that lactic acid bacteria may play a positive role in reducing uric acid concentration in the blood through various mechanisms, such as degrading purine substances in the intestine, promoting uric acid excretion, and inhibiting uric acid production .
In addition, the function of lactic acid bacteria in regulating the intestinal environment, improving the diversity of intestinal microorganisms and promoting the growth of beneficial bacteria may also indirectly affect the metabolic process of uric acid. Therefore, exploring the potential of lactic acid bacteria in regulating uric acid concentration has become a hot topic in many current studies. These studies not only provide new insights into the health effects of lactic acid bacteria, but also provide new directions for the prevention and treatment of gout and other diseases related to abnormal uric acid.
This study will explore the potential role and mechanism of lactic acid bacteria in lowering uric acid and evaluate its feasibility as an adjuvant therapy.
- Conditions
- Gout
- Being tested
- Give the Placebo and test article
- Medical subject headings
- Gout
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Give the Placebo and test articleDietary supplement
Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.
Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days.
| Study group | Role | What they receive |
|---|---|---|
| Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) | Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs Receives: Dietary Supplement: Give the Placebo and test article |
What is being measured
The primary outcome is the main question the study is designed to answer.
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later. Blood sampling points were week 0, week 2, week 6
Measured: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood sampling were at week 0, week 2, week 6.
Secondary outcomes (7)
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Measured: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week 0, week 2 and week 6.
Measured: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days. Blood samlping were at week 0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of Hematology: WBC, PLT (Unit: 10^3 Cells/μL).
This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Measured: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of Hematology: Hb, MCHC (Unit: g/dL).
This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Measured: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of Hematology: MCV (Unit: fL).
This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Measured: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of Hematology: MCH (Unit: pg).
This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Measured: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of Hematology:RBC (Unit: 10^6 Cells/μL).
This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later.Through the analysis of serum biochemistry, hematology and various cytokines in serum, we can obtain the effects of "LUA probiotics" on the human body after consumption. Blood samlping were at week0, week 2 and week 6.
Measured: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2025
- Study start18 Jul 2022
- Primary completion29 Mar 2024
- Study completion8 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for GoutStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (actual)
- Target duration
- 3 Weeks
Sponsor and investigators
- Lead sponsor
- Grape King Bio Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Min-Chih Hsu, Master, Principal investigator, Super Laboratory Co., Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06969469
- Sponsor's protocol ID
- Grape King Bio Ltd
- Status last verified
- Jun 2026
- First submitted
- 5 May 2025
- Last updated
- 22 Jun 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Cheng S, Shan L, You Z, Xia Y, Zhao Y, Zhang H, Zhao Z. Dietary patterns, uric acid levels, and hyperuricemia: a systematic review and meta-analysis. Food Funct. 2023 Aug 29;14(17):7853-7868. doi: 10.1039/d3fo02004e.
PubMed 37599588
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- To Evaluate the Influence of (LUA Probiotics) on Uric Acid
- ClinicalTrials.gov ID
- NCT06969469
- Acronym / sponsor ID
- Grape King Bio Ltd
- Conditions
- Gout
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Grape King Bio Ltd.Industry (pharma, biotech, devices)
- Study start
- 18 Jul 2022 (actual)
- Primary completion
- 29 Mar 2024 (actual)
- Study completion
- 8 Aug 2024 (actual)
- First posted
- 13 May 2025 (actual)
- Results
- Posted 22 Jun 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate the efficacy of the lactic acid bacteria "LUA probiotics" in reducing serum uric acid levels. The use of health supplements prior to the onset of gout symptoms is proposed as a preventive strategy to mitigate the development of gout and to reduce the subsequent reliance on long-term pharmacological treatments. Hyperuricemia is the presence of abnormally high levels of uric acid in the blood serum. Long-term hyperuricemia is a major factor in causing gout. In addition, hyperuricemia is associated with many diseases. Therefore, the prevention and treatment of hyperuricemia has gradually attracted attention. In recent years, studies have pointed out that whether from cell experiments or animal experiments, lactic acid bacteria (LAB) have the effect of lowering uric acid. However, there is a lack of rigorous clinical observational studies to further explore whether lactic acid bacteria really have the effect of lowering uric acid. This product "LUA Probiotics" is a probiotic developed and produced by the Longtan Branch of Grape King Biotechnology Co., Ltd. Its main ingredients include Lactobacillus reuteri (Lactobacillus reuteri), β-carotene, silicon dioxide and magnesium stearate. This product is not yet commercially available.
Detailed description
This study aims to investigate the efficacy of the lactic acid bacteria "LUA probiotics" in reducing serum uric acid levels. The use of health supplements prior to the onset of gout symptoms is proposed as a preventive strategy to mitigate the development of gout and to reduce the subsequent reliance on long-term pharmacological treatments. In recent years, lactic acid bacteria have gradually been recognized to have many benefits for human health, especially in regulating intestinal flora, enhancing immune function, and improving metabolism. Uric acid is a product of purine metabolism in the human body. Excessive uric acid concentration can cause hyperuricemia, which in turn increases the risk of gout attacks. The formation of hyperuricemia is related to multiple factors, including poor eating habits, genetic factors, and metabolic disorders.
As research on intestinal microbiota deepens, scientists have discovered that changes in intestinal flora may have a certain impact on metabolic diseases, including hyperuricemia. As an important type of probiotics, lactic acid bacteria have the ability to improve the structure of intestinal flora, regulate immune response and have anti-inflammatory effects. Recent studies have shown that lactic acid bacteria may play a positive role in reducing uric acid concentration in the blood through various mechanisms, such as degrading purine substances in the intestine, promoting uric acid excretion, and inhibiting uric acid production .
In addition, the function of lactic acid bacteria in regulating the intestinal environment, improving the diversity of intestinal microorganisms and promoting the growth of beneficial bacteria may also indirectly affect the metabolic process of uric acid. Therefore, exploring the potential of lactic acid bacteria in regulating uric acid concentration has become a hot topic in many current studies. These studies not only provide new insights into the health effects of lactic acid bacteria, but also provide new directions for the prevention and treatment of gout and other diseases related to abnormal uric acid.
This study will explore the potential role and mechanism of lactic acid bacteria in lowering uric acid and evaluate its feasibility as an adjuvant therapy.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Weeks
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) | – | Dietary Supplement: Give the Placebo and test articlePatients with hyperuricemia (uric acid level 7.5 mg/dL or above) who are not taking uric acid-lowering drugs, patients with gout who are not taking uric acid-lowering drugs |
Who may qualify
- Ages
- 20 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 1. Collect 20 people, both male and female, aged 20 or above. 2. Be conscious, willing to participate in the clinical observational research project, and complete the signed written consent form. 3. Patients with hyperuricemia (uric acid level above 7.5 mg/dL) who have not taken uric acid-lowering drugs, and patients with gout who have not taken uric acid-lowering drugs, regardless of gender.
Key inclusion criteria (3 listed)
- Collect 20 people, both male and female, aged 20 or above.
- Be conscious, willing to participate in the clinical observational research project, and complete the signed written consent form.
- Patients with hyperuricemia (uric acid level above 7.5 mg/dL) who have not taken uric acid-lowering drugs, and patients with gout who have not taken uric acid-lowering drugs, regardless of gender.
Key exclusion criteria (11 listed)
- Patients diagnosed by a physician as suffering from a major injury or illness listed by the National Health Insurance Administration.
- Pregnant women or women who plan to become pregnant within six months.
- Patients with abnormal liver function (AST, ALT greater than 2 times the upper limit of normal).
- Patients with abnormal renal function (serum creatinine > 1.5 mg/dL).
- Patients with gastrointestinal dysfunction (surgery, frequent diarrhea).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Give the Placebo and test articlePhase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days. Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days. | Dietary supplement | Patients with hyperuricemia (uric acid level 7.5 mg/dL or above) |
Primary outcome
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL).
Time frame: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood sampling were at week 0, week 2, week 6.
This study aims to evaluate whether taking lactic acid bacteria "LUA probiotics" can reduce blood uric acid levels, and prevent gout symptoms by taking health foods before they occur, avoiding the need to take medication later. Blood sampling points were week 0, week 2, week 6
7 secondary outcomes
The 20 Subjects Should be Detected the Value of Hematology: Hct, RDW-CV, Neu, Lym, Mon, Eos, Bas (Unit: %).
Time frame: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of 8 Kinds of Cytokine: IL-1β, IL-6, IL-10, IL-13, IL-17, IL-18, TNF-α, IFN-γ (Unit: pg/mL).
Time frame: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days. Blood samlping were at week 0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of Hematology: WBC, PLT (Unit: 10^3 Cells/μL).
Time frame: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of Hematology: Hb, MCHC (Unit: g/dL).
Time frame: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of Hematology: MCV (Unit: fL).
Time frame: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of Hematology: MCH (Unit: pg).
Time frame: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
The 20 Subjects Should be Detected the Value of Hematology:RBC (Unit: 10^6 Cells/μL).
Time frame: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood samlping were at week0, week 2 and week 6.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 37599588Cheng S, Shan L, You Z, Xia Y, Zhao Y, Zhang H, Zhao Z. Dietary patterns, uric acid levels, and hyperuricemia: a systematic review and meta-analysis. Food Funct. 2023 Aug 29;14(17):7853-7868. doi: 10.1039/d3fo02004e.
- Individual participant dataSharing planned: No
Related trials for Gout
RecruitingPhase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Tophaceous Gout
Not yet recruitingPhase 3
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
Gout Disease
Enrolling by invitation
The Remote Monitoring of Gout Study
Gout Initiating Urate-loweringUrate-lowering Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Min-Chih Hsu, Master principal investigator
Super Laboratory Co., Ltd.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gout, run by Grape King Bio Ltd. at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Jun 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The 20 Subjects Should be Detected the Value of Uric Acid, Glucose ac, TG, TC, HDL and LDL (Unit: mg/dL). (time frame: Phase 1: The 20 subjects take 2 capsules (500 mg/capsule)/Placebo after dinner for 14 days. Phase 2: The same 20 subjects take 2 capsules (500 mg/capsule)/test article after dinner for 28 days.Blood sampling were at week 0, week 2, week 6.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06969469, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.